LuciCapma — Capmatinib 200 mg, 60 pcs, Lucius

LuciCapma — Capmatinib Tablets 200 mg, 60 Tablets

Product code: 497

31290₴ 34061₴ -8% On order · from 10 days

Analogues

Capmaxen LuciCapma
1
Active ingredient
Dosage
200 mg
Dosage form Tablets
Tablets per pack 60

LuciCapma is an advanced targeted antineoplastic agent belonging to the kinase inhibitor class, indicated for the treatment of non-small cell lung cancer. The active pharmaceutical ingredient is capmatinib at a strength of 200 mg supplied as film-coated oral tablets (Capmatinib Tablets 200 mg). The product is developed and manufactured by Lucius Pharmaceuticals.

Capmatinib is a highly selective oral inhibitor of the MET receptor (including MET exon 14 skipping mutations [METex14] and MET gene amplification). Activating MET mutations and aberrations play a pivotal role in tumor growth, angiogenesis, and metastasis across various malignancies. Capmatinib effectively blocks MET kinase activity, inducing tumor cell apoptosis. Capmatinib also readily crosses the blood-brain barrier, providing high clinical efficacy against brain metastases.

Supplied in a package containing 60 tablets of 200 mg. Intended exclusively for oral administration under the strict supervision of an oncologist.

Key Clinical Features and Advantages of LuciCapma 200 mg:

  • ✅ Highly Selective MET Inhibition: Targeted suppression of METex14 mutations and MET amplification.
  • ✅ CNS Metastases Activity: Ability to cross the blood-brain barrier for effective intracranial tumor control.
  • ✅ Proven Clinical Efficacy: High overall response rates in both treatment-naive and previously treated NSCLC patients harboring MET alterations.
  • ✅ Convenient Oral Dosing: Taken orally twice daily regardless of food intake.
  • ✅ Lucius Pharmaceuticals Standards: High-quality, accessible generic alternative to the originator product (Tabrecta).

LuciCapma is supplied as film-coated tablets for oral administration.

Qualitative and Quantitative Composition per Tablet:

  • Active Ingredient: Capmatinib (as capmatinib hydrochloride hydrate) — 200 mg.
  • Excipients: Microcrystalline cellulose, crospovidone, mannitol, magnesium stearate, colloidal anhydrous silica. Coating: hypromellose, titanium dioxide, macrogol, talc, iron oxide yellow/red.

Packaging and Presentation: Film-coated tablets, 200 mg strength. Each package contains 60 tablets along with prescribing information. Labeled with LuciCapma (Capmatinib Tablets 200 mg) and Lucius Pharmaceuticals corporate graphics.

Pharmacodynamics:
Capmatinib is a kinase inhibitor that targets MET, including mutant variants such as exon 14 skipping (METex14). MET mutations resulting in exon 14 skipping produce a truncated MET protein lacking the regulatory domain, leading to decreased protein degradation and constitutive MET kinase activation. Capmatinib inhibits hepatocyte growth factor (HGF)-induced MET phosphorylation, MET-mediated phosphorylation of downstream signaling proteins, and the proliferation of MET-dependent tumor cell lines.

Pharmacokinetics:

  • Absorption: Following oral administration, capmatinib is rapidly absorbed. Peak plasma concentration (Tmax) is achieved within 1 to 2 hours. Food intake has no clinically significant effect on bioavailability.
  • Distribution: Human plasma protein binding is approximately 96%. Capmatinib distributes into brain tissues.
  • Metabolism: Extensively metabolized in the liver, primarily via CYP3A4 and aldehyde oxidase.
  • Elimination: Excreted predominantly via feces (approx. 78% as metabolites and unchanged drug) and renally (approx. 22%). Terminal elimination half-life (T1/2) is approximately 6.5 hours.

LuciCapma is indicated in adult patients for:

  • Non-Small Cell Lung Cancer (NSCLC): Treatment of patients with metastatic non-small cell lung cancer harboring mutations that lead to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by a validated test (as first-line therapy or in previously treated patients).

LuciCapma is administered orally twice daily every day.

Dosing Regimen:
The recommended standard dose is 400 mg (two 200 mg tablets) twice daily (total daily dose of 800 mg).

Administration Guidelines:
Tablets should be taken regardless of food intake with water. Tablets must be swallowed whole; do not break, crush, or chew. If a dose is missed or vomiting occurs after ingestion, take the next dose at the scheduled time (do not double doses to make up for a missed dose).

Administration of LuciCapma is contraindicated in:

  • Hypersensitivity: Known hypersensitivity to capmatinib or any excipient.
  • Pregnancy and Lactation: Strictly contraindicated in pregnant or breastfeeding women.
  • Pediatric Population: Safety and efficacy in patients under 18 years have not been established.
  • Severe Hepatic Impairment: Pronounced liver dysfunction.

Capmatinib is metabolized by CYP3A4 and acts as a modulator of specific enzymes and transporters:

  • Strong CYP3A4 Inducers (rifampicin, carbamazepine, phenytoin, St. John's Wort): Significantly decrease capmatinib plasma concentrations and reduce antitumor efficacy. Avoid concurrent use.
  • P-glycoprotein (P-gp) and BCRP Substrates: Capmatinib may inhibit these transporters, increasing plasma concentrations of co-administered substrates (e.g., digoxin, rosuvastatin).
  • Strong CYP3A4 Inhibitors: May elevate systemic capmatinib exposure (use with caution if co-administration is necessary).

Pregnancy:
LuciCapma is contraindicated during pregnancy. Based on its mechanism of action, capmatinib may cause embryotoxicity and teratogenic harm when administered to pregnant women. Females of reproductive potential and male partners must utilize effective, reliable contraception during treatment and for at least 1 week following the final dose.

Lactation:
Excretion of capmatinib into human breast milk is unstudied. Breastfeeding must be discontinued during treatment.

The most frequent and clinically significant adverse reactions include:

  • Peripheral Edema (Very Common): Development of lower extremity and generalized edema, requiring medical monitoring and potential dose reduction.
  • Gastrointestinal Tract: Nausea, vomiting, diarrhea, constipation, decreased appetite, abdominal pain.
  • Laboratory Abnormalities: Elevations in serum creatinine and liver transaminases (ALT, AST).
  • General Disorders: Fatigue, dyspnea, asthenia.
  • Severe Effects: Interstitial lung disease (pneumonitis), which can be severe and requires immediate drug discontinuation upon onset of pulmonary symptoms.

Symptoms:
Specific acute overdose symptoms of capmatinib are unestablished. Anticipated manifestations include exacerbated peripheral edema, nausea, and laboratory abnormalities.

Treatment:
No specific antidote exists. In case of overdose, discontinue capmatinib and initiate supportive and symptomatic care under vital organ monitoring.

Storage Requirements for LuciCapma 200 mg:

  • 🌡️ Temperature Range: Store in original packaging in a dry place protected from light at temperatures below 30 °C.
  • 👶 Safety Precautions: Keep strictly out of reach of children (cytotoxic antineoplastic agent).
  • ⏳ Shelf Life: Stated on carton and blister pack. Do not use past expiration date. Prescription-only oncology medicine.

To verify authenticity of genuine LuciCapma 200 mg manufactured by Lucius Pharmaceuticals, inspect the following security and visual features:

  • ✅ Security Hologram & Scratch Code: Outer carton features an official Lucius Pharmaceuticals anti-counterfeit holographic seal with a scratch-off verification code for online validation via the manufacturer's official portal.
  • ✅ Corporate Branding: High-resolution printing displaying Lucius Pharmaceuticals graphics and Capmatinib Tablets 200 mg.
  • ✅ Factory Markings: Clearly printed Batch No., Mfg. Date, and Exp. Date matching across outer packaging and internal blister packs.
  • ✅ Prescribing Information: Includes an official product leaflet inside the outer carton.
On order · from 10 days
100% original product
Delivery across Ukraine
1

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 14.11.2026

Customer reviews

No reviews yet

Your review can be the first!

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00